Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib - Summary - MDSpire

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

  • By

  • Francesca Palandri

  • Elena M. Elli

  • Giuseppe Auteri

  • Massimiliano Bonifacio

  • Giulia Benevolo

  • Florian H. Heidel

  • Simona Paglia

  • Malgorzata M. Trawinska

  • Costanza Bosi

  • Elena Rossi

  • Mario Tiribelli

  • Alessia Tieghi

  • Alessandra Iurlo

  • Nicola Polverelli

  • Giovanni Caocci

  • Gianni Binotto

  • Francesco Cavazzini

  • Eloise Beggiato

  • Daniela Cilloni

  • Caterina Tatarelli

  • Francesco Mendicino

  • Maurizio Miglino

  • Monica Bocchia

  • Monica Crugnola

  • Camilla Mazzoni

  • Andrea D. Romagnoli

  • Giovanni Rindone

  • Sara Ceglie

  • Alessandra D’Addio

  • Eleonora Santoni

  • Daniele Cattaneo

  • Daniela Bartoletti

  • Roberto M. Lemoli

  • Mauro Krampera

  • Antonio Cuneo

  • Gianpietro C. Semenzato

  • Roberto Latagliata

  • Elisabetta Abruzzese

  • Nicola Vianelli

  • Michele Cavo

  • Alessandro Andriani

  • Valerio De Stefano

  • Giuseppe A. Palumbo

  • Massimo Breccia

  • May 3, 2023

  • 0 min

Share

Objective:

To explore specific clinical and demographic features associated with Covid19 disease severity and survival outcomes in ruxolitinib-treated patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN).

Key Findings:
  • 14.2% of patients acquired Covid19, with a notably higher incidence in MF patients, indicating a potential need for targeted interventions.
  • Vaccination significantly reduced the likelihood of acquiring Covid19, highlighting the importance of vaccination in this vulnerable population.
  • Hospitalization rates were higher in older patients and those with lower platelet counts, suggesting specific risk profiles that may require closer monitoring.
Interpretation:

Ruxolitinib-treated MPN patients are at increased risk for severe Covid19 outcomes, with vaccination providing a protective effect by enhancing immune response.

Limitations:
  • The retrospective design may introduce bias, potentially affecting the reliability of the associations observed.
  • Limited generalizability due to the specific patient population, which may not represent all MPN patients.
Conclusion:

Identifying risk factors in ruxolitinib-treated patients can aid in decision-making for Covid19 management and treatment strategies, ultimately improving patient outcomes.

Original Source(s)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

  • by Francesca Palandri, Elena M. Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Florian H. Heidel, Simona Paglia, Malgorzata M. Trawinska, Costanza Bosi, Elena Rossi, Mario Tiribelli, Alessia Tieghi, Alessandra Iurlo, Nicola Polverelli, Giovanni Caocci, Gianni Binotto, Francesco Cavazzini, Eloise Beggiato, Daniela Cilloni, Caterina Tatarelli, Francesco Mendicino, Maurizio Miglino, Monica Bocchia, Monica Crugnola, Camilla Mazzoni, Andrea D. Romagnoli, Giovanni Rindone, Sara Ceglie, Alessandra D’Addio, Eleonora Santoni, Daniele Cattaneo, Daniela Bartoletti, Roberto M. Lemoli, Mauro Krampera, Antonio Cuneo, Gianpietro C. Semenzato, Roberto Latagliata, Elisabetta Abruzzese, Nicola Vianelli, Michele Cavo, Alessandro Andriani, Valerio De Stefano, Giuseppe A. Palumbo, Massimo Breccia

  • May 3, 2023

Related Content

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model